Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975011 | 1.00 | PIM1 (0.82) | PIM1PIM2 | |
| SCHEMBL1975017 | 1.00 | PIM1 (0.82) | PIM1PIM2 | |
| Hydrochloric Acid SCHEMBL1975210 | 0.99 | PIM1 (0.81) | PIM1PIM2 | |
| Hydrochloric Acid SCHEMBL1975211 | 0.99 | PIM1 (0.81) | PIM1PIM2 | |
| Hydrochloric Acid SCHEMBL1975213 | 0.99 | PIM1 (0.81) | PIM1PIM2 | |
| SCHEMBL1980511 | 0.90 | PIM1 (1.00) | PIM1PIM2 | |
| SCHEMBL1980512 | 0.90 | PIM1 (1.00) | PIM1PIM2 | |
| SCHEMBL1980513 | 0.90 | PIM1 (1.00) | PIM1PIM2 | |
| SCHEMBL1977242 | 0.89 | PIM1 (1.00) | PIM1PIM2 | |
| Hydrochloric Acid SCHEMBL1976654 | 0.89 | PIM1 (0.98) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2334677-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-10-09 | — | — | EP | claimed |
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8575145-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2334677-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885 |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | PIM1 2/4885PIM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.